Testing the amyloid hypothesis of Alzheimer's disease in vivo
- PMID: 20189880
- PMCID: PMC3274723
- DOI: 10.1016/S1474-4422(10)70055-7
Testing the amyloid hypothesis of Alzheimer's disease in vivo
Figures

Comment on
-
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26. Lancet Neurol. 2010. PMID: 20189881 Clinical Trial.
Similar articles
-
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26. Lancet Neurol. 2010. PMID: 20189881 Clinical Trial.
-
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065. J Alzheimers Dis. 2016. PMID: 27163805 Clinical Trial.
-
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2. Neurology. 2018. PMID: 29429971 Clinical Trial.
-
Clinical Aspects of Alzheimer's Disease.Adv Neurobiol. 2017;15:31-53. doi: 10.1007/978-3-319-57193-5_2. Adv Neurobiol. 2017. PMID: 28674977 Review.
-
Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.Q J Nucl Med Mol Imaging. 2011 Jun;55(3):265-79. Q J Nucl Med Mol Imaging. 2011. PMID: 21532540 Review.
Cited by
-
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.Annu Rev Med. 2013;64:367-83. doi: 10.1146/annurev-med-092611-084441. Annu Rev Med. 2013. PMID: 23327526 Free PMC article. Review.
-
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012. J Neurosci. 2012. PMID: 22357853 Free PMC article.
-
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.PLoS One. 2012;7(11):e50317. doi: 10.1371/journal.pone.0050317. Epub 2012 Nov 27. PLoS One. 2012. PMID: 23209707 Free PMC article.
-
New pathway links γ-secretase to inflammation and memory while sparing notch.Ann Neurol. 2011 Jan;69(1):5-7. doi: 10.1002/ana.22310. Ann Neurol. 2011. PMID: 21280069 Free PMC article. No abstract available.
-
A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.J Neurochem. 2011 Oct;119(1):189-201. doi: 10.1111/j.1471-4159.2011.07389.x. Epub 2011 Aug 22. J Neurochem. 2011. PMID: 21781116 Free PMC article.
References
-
- Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de LIano SRM, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. [11C]PiB PET supports reduced cortical fibrillar Aβ in Alzheimer’s disease patients treated with bapineuzumab. Lancet Neurol. 2010 this issue. - PubMed
-
- Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006 Nov;65(11):1040–8. - PubMed
-
- Swanoski MT. Homotaurine: a failed drug for Alzheimer’s disease and now a nutraceutical for memory protection. Am J Health Syst Pharm. 2009 Nov 1;66(21):1950–3. - PubMed
-
- Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 16;302(23):2557–64. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical